

![]() |
Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation |
|
Authors | ||
Published in | Chest. 1999, vol. 116, no. 5, p. 1265-72 | |
Abstract | Cytomegalovirus (CMV) disease is one of the major challenges of lung transplantation that may determine outcome. The benefits of ganciclovir prophylaxis seem indisputable, but no consensus has been reached on the optimal duration of therapy. Results with different protocols suggest that efficacy is related to the duration of treatment. | |
Keywords | Adolescent — Adult — Antibiotic Prophylaxis/economics/methods — Antibodies, Viral/analysis — Antiviral Agents/administration & dosage/economics/therapeutic use — Bronchoalveolar Lavage Fluid/virology — Child — Cost-Benefit Analysis — Costs and Cost Analysis — Cytomegalovirus/immunology/isolation & purification — Cytomegalovirus Infections/economics/epidemiology/prevention & control/virology — Female — Follow-Up Studies — Ganciclovir/administration & dosage/economics/therapeutic use — Graft Rejection/immunology/prevention & control — Humans — Immunosuppressive Agents/therapeutic use — Incidence — Infusions, Intravenous — Lung Transplantation — Male — Middle Aged — Pneumonia, Viral/economics/epidemiology/prevention & control/virology — Prospective Studies — Survival Rate — Switzerland/epidemiology — Treatment Outcome | |
Identifiers | PMID: 10559085 | |
Full text | ||
Structures | ||
Citation (ISO format) | GERBASE, Margaret et al. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation. In: Chest, 1999, vol. 116, n° 5, p. 1265-72. doi: 10.1378/chest.116.5.1265 https://archive-ouverte.unige.ch/unige:72647 |